Former President Joe Biden recently underwent surgery to remove skin cancer lesions and has been left with a large scar on his forehead, his office says. Biden’s representative, Kelly Scully, ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ...
Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT ...
Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results